FDA Expands Approval for Alnylam’s Drug to Treat Rare Heart Disease
By Reuters The Food and Drug Administration approved Alnylam’s drug to treat a rare and deadly heart disease on Thursday, allowing the entry of a new type of medicine in a market dominated by Pfizer’s blockbuster Vyndaqel. Alnylam is banking on the success of the drug, chemically called vutrisiran, to reach profitability and invest in future treatments. Its drug will compete in the…
More Stories
Thrivent Financial for Lutherans Sells 355 Shares of Target Co. (NYSE:TGT)
Thrivent Financial for Lutherans cut its holdings in shares of Target Co. (NYSE:TGT – Free Report) by 1.3% during the...
Integras Partners LLC Buys New Shares in Alphabet Inc. (NASDAQ:GOOGL)
Integras Partners LLC purchased a new stake in Alphabet Inc. (NASDAQ:GOOGL – Free Report) in the 4th quarter, according to...
JPL Wealth Management LLC Takes $7.93 Million Position in Alphabet Inc. (NASDAQ:GOOGL)
JPL Wealth Management LLC acquired a new position in Alphabet Inc. (NASDAQ:GOOGL – Free Report) in the fourth quarter, HoldingsChannel...
Thrivent Financial for Lutherans Has $3.71 Million Stake in CME Group Inc. (NASDAQ:CME)
Thrivent Financial for Lutherans lessened its position in CME Group Inc. (NASDAQ:CME – Free Report) by 5.2% in the fourth...
Maryland State Retirement & Pension System Has $36.38 Million Position in JPMorgan Chase & Co. (NYSE:JPM)
Maryland State Retirement & Pension System lowered its stake in shares of JPMorgan Chase & Co. (NYSE:JPM) by 7.9% in...
Xponance Inc. Purchases 3,608 Shares of JPMorgan Chase & Co. (NYSE:JPM)
Xponance Inc. increased its position in JPMorgan Chase & Co. (NYSE:JPM) by 0.9% in the 4th quarter, HoldingsChannel reports. The...